Seekin Alpha had two really good articles recently about Prolor 1) Danish drug giant Novo Nordisk (NVO) is currently in phase III trials with Liraglutide, an application based on a naturally occurring human peptide that's delivered in the form of a once-daily injection. The company currently has the lion's share of the market, but could soon be overtaken by Prolor Biotech (PBTH), which is developing a once-weekly version of Novo Nordisk's protein therapy. Prolor's breakthrough would make administration far more feasible and therefore poses a greater threat to those developers currently ahead in the race.
2) Prolor Biotech is an Israel-based company that has products that are going through the FDA approval process that aim to provide a more user-friendly version of existing Human Growth Hormone treatment. The main axe on this name is Summer Street Research Partners. Their latest DCF model points to a price target of $8 per share. The current stock price reflects a 32% discount from the true equity value